Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Brigham and Women's Hospital · St. Michael's Hospital · +26 more institutions
Abstract
The efficacy and safety of sodium-glucose cotransporter 2 inhibitors such as sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic kidney disease with or without albuminuria have not been well studied.
of body-surface area), and risks for cardiovascular disease were randomly assigned in a 1:1 ratio to receive sotagliflozin or placebo. The primary end point was changed during the trial to the composite of the total number of deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure. The trial ended early owing to loss of funding.
Citation impact
- FWCI
- 98.20
- Percentile
- 100%
- References
- 50
Authors
20- DLDeepak L. BhattCorresponding
Brigham and Women's Hospital, St. Michael's Hospital, University of Colorado Anschutz Medical Campus
- MSMichael Szarek
State University of New York, SUNY Downstate Health Sciences University, University of Colorado Anschutz Medical Campus
- BPBertram Pitt
University of Michigan, University of Colorado Anschutz Medical Campus
- CPChristopher P. Cannon
Brigham and Women's Hospital, St. Michael's Hospital, University of Colorado Anschutz Medical Campus
- LALawrence A. Leiter
University of Toronto, University of Colorado Anschutz Medical Campus
Topics & keywords
- Diabetes mellitus
- Medicine
- Kidney disease
- Disease
- Intensive care medicine
- Internal medicine
- Endocrinology
- Good health and well-being